Effect of atorvastatin on hs‐CRP in acute coronary syndrome

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Markers of inflammation are being investigated as predictors of coronary ischaemic events. All major statins have shown almost similar and significant efficacy in reducing C-reactive protein (CRP) concentrations in acute coronary syndrome (ACS), but atorvastatin was used in a high dose (80 mg).• This study was designed to evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS. WHAT THIS STUDY ADDS• A lower dose of atorvastatin (20 mg) was effective in decreasing hs-CRP and LDL concentrations in as short a duration as 4 weeks. The use of a lower dose of atorvastatin in patients of ACS can offer an attractive approach for early treatment of ACS patients. AIMSTo evaluate the effect of a lower dose (20 mg) of atorvastatin on hs-CRP concentrations in patients with ACS. METHODSGroup A (n = 50) patients received atorvastatin 20 mg day -1 for 4 weeks in addition to standard anti-anginal treatment. Group B (n = 50) patients received standard anti-anginal treatment without atorvastatin. RESULTShs-CRP concentrations decreased in both groups, but the decrease was greater in group A. The decrease in hs-CRP was also significantly greater in the subgroups of smoking, hypertension and past history of cardiovascular disease with atorvastatin. CONCLUSIONSThe use of a lower dose (20 mg) of atorvastatin can offer an attractive approach for early treatment of patients with ACS.

Compare the effect of high and low doses of atorvastatin on the levels of high-sensitivity C-reactive protein in patients with acute coronary syndrome

“…29 In this study, high-dose atorvastatin significantly increased HDL and decreased LDL levels, which was consistent with other similar studies. [30][31][32] In this study, consumption of high-dose statins could significantly reduce the amount of hs-CRP compared to lower doses. Meanwhile, in the studies conducted by Macin and Vasilieva it was revealed that CRP level in ACS decreased quickly after taking atorvastatin.…”

Prevalence of Novel Risk Factors in Patients of Acute Coronary Syndrome in Eastern India: A Detailed Analysis

“…High hsCRP value more in younger age group explains occurrence of high premature Coronary Artery Disease in our study and so in India 19 . So screening of population in the younger age group for high hs-CRP may be very useful as targeting those with statin therapy can reduce the mortality, morbidity and overall burden of health care 20 .…”

Ramadan Fasting And Cardiac Biomarkers In Patients With Multiple Cardiovascular Disease Risk Factors

“…Previous studies had evaluated interrelationships between CRP and metabolic syndrome, which is comprised of waist circumference, dyslipidaemia, abnormal glucose tolerance and BP 22 it showed that metabolic syndrome is associated with increased levels of CRP (36). CRP is considered as important biomarker in metabolic syndrome has been proved 23 Lowering hs-CRP by lipid lowering agents like statins had shown a beneficial effect on cardiovascular risk in many previous studies (37-39) Ankur et al 24 found a greater reduction in hs-CRP up to 22-40% in patients with acute coronary syndrome treated with atorvastatin for 4 weeks. This beneficial effect was independent of statin effects on cholesterol.…”